Results 121 to 130 of about 84,477 (249)

Ultrasound-Guided Intra-Articular Infiltration of Hyaluronic Acid, Lidocaine, and Methylprednisolone in Patients with Temporomandibular Disorders (TMD): A Preliminary Pilot Case Series. [PDF]

Clin Pract
Messina G, Mantia F, Cataldo P, Iovane A.   +3 more
europepmc   +1 more source

The immunological landscape of the area postrema in neuromyelitis optica spectrum disorders

Brain Pathology, EarlyView.
Aquaporin‐4 antibody‐positive neuromyelitis spectrum disorder is characterized by large tissue destructive lesions in medulla, spinal cord, and optic nerves, with only partial recovery from clinical symptoms, and by lesions with very little tissue destruction and mostly complete recovery from clinical symptoms, as seen in the area postrema ...
Qian Yu, Yoshiki Takai, Naoya Yamazaki, Sarah Brandl, Katharina M. Mair, Thibault Bouderlique, Maria Eleni Kastriti, Igor Adameyko, Romana Höftberger, Markus Reindl, Jan Bauer, Monika Bradl   +11 more
wiley   +1 more source

Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review. [PDF]

Front Oncol
Tang S, Li N, Ma J.
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Case Report: Ruxolitinib for systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome: two pediatric cases and literature review. [PDF]

Front Pediatr
Liu H, Wang Z, Zhang W.
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis. [PDF]

Rheumatology (Oxford)
McClure ME, Sundararajan A, Nelveg-Kristensen KE, Leibowitz M, Coates ML, McGovern D, Chen-Xu M, Sagy I, Granak K, Quarrell T, Suresh S, Watson M, Kronbichler A, Willcocks L, Smith R, Jayne DRW, Jones RB.   +16 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Weil's disease: rapid recovery following corticosteroid treatment: a case report. [PDF]

Rev Inst Med Trop Sao Paulo
Şahin AM, Atçı-Koç İ, Çetin S.
europepmc   +1 more source

A Systematic Review of Literature: TNF-α Blockers and JAK Inhibitors for the Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme. [PDF]

Health Sci Rep
Salehi S, Torabi P, Abbaspour M, Hajizadeh N, Sadeghi S, Jafarzadeh A, Goodarzi A.   +6 more
europepmc   +1 more source